Search | Clinical Trials Finder

Conditions: Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions: Computed Tomography, Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Positron Emission Tomography, Radiation Therapy, Single Photon Emission Computed Tomography, Technetium Tc-99m Albumin Aggregated, Technetium Tc-99m Sulfur Colloid; Procedure · Radiation · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Kawasaki Disease
Interventions: Technetium Tc99m Sestamibi; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 4 Years to 16 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 7
States / cities: Miami, Florida • Honolulu, Hawaii • Chicago, Illinois + 4 more

Conditions: Coronary Artery Disease
Interventions: Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose; Radiation
Lead sponsor: Cell>Point LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Cystic Fibrosis
Interventions: Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Arthritis, Rheumatoid
Interventions: Tc99m-tilmanocept, SPECT Imaging (60 Minutes post-injection), SPECT Imaging (180 Minutes post-injection), Whole body planar SPECT imaging (15 Minutes post-injection), Whole body planar SPECT imaging (60 Minutes post-injection), Whole body planar SPECT imaging (180 Minutes post-injection), Whole body planar SPECT imaging (18-20 Hours post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after injection), Blood Collection for PK Testing (15 minutes post injection), Blood Collection for PK Testing (60 minutes post injection), Blood Collection for PK Testing (180 minutes post injection), Blood Collection for PK Testing (18-20 hours post injection), Planar Image with both Hands in Field of View; Drug · Procedure
Lead sponsor: Navidea Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kettering, Ohio

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Technetium Tc 99m EC20; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 2
States / cities: Rochester, Minnesota • Houston, Texas

Conditions: Lung Cancer
Interventions: Real-time Position Management system, Discovery ST multislice PET/CT scanner, Infinia Hawkeye SPECT/CT gamma camera, Pinnacle3 treatment planning system, SKYLight nuclear camera, DTPA, TECHNETIUM TC 99M MAA; Device · Drug
Lead sponsor: Billy W. Loo Jr.; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Stage IV Skin Melanoma
Interventions: Laboratory Biomarker Analysis, Radionuclide Imaging, Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2; Other · Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer
Interventions: SiennaXP, Technetium Tc99m Sulfur Colloid, Isosulfan blue dye; Device · Drug
Lead sponsor: Endomagnetics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 6
States / cities: La Jolla, California • Sacramento, California • San Francisco, California + 3 more

Conditions: Eyelid Sebaceous Gland Carcinoma
Interventions: Lymph Node Mapping, Sentinel Lymph Node Biopsy, Technetium Tc-99m Sulfur Colloid; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovary Cancer
Interventions: EC1456, 99mTc-Etarfolatide; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Concord, North Carolina

Conditions: Rheumatoid Arthritis
Interventions: TC99m-tilmanocept; Drug
Lead sponsor: Navidea Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: Beverly Hills, California • San Francisco, California • Avon Park, Florida + 10 more

Conditions: Breast Cancer
Interventions: Radiolabeled (99mTc) GP (Glycopeptide); Radiation
Lead sponsor: SeeCure LLC; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Uric Acid Nephrolithiasis
Interventions: 123I-BMIPP, 99mTc-MAG3; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 99 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Cystic Fibrosis
Interventions: Absorptive clearance scan; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Coronary Artery Disease
Interventions: Technetium Tc99m Tetrofosmin injections, Thallous Chloride T1-201; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Prostate Cancer
Interventions: 99mTc-MIP-1404; Drug
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Modified Barium Swallow, Paclitaxel, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography, Technetium Tc 99m-labeled Tilmanocept, Technetium Tc-99m Sulfur Colloid; Procedure · Drug · Other + 1 more
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Nonalcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis
Interventions: Tc 99M Sulfur Colloid, Tc99m-tilmanocept; Drug
Lead sponsor: Navidea Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Kettering, Ohio

Conditions: Pulmonary Embolism
Interventions: Technegas V SPECT imaging, Xenon-133 Ventilation Planar imaging; Drug
Lead sponsor: Cyclomedica Australia PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: St Louis, Missouri • New York, New York

Conditions: Stage I Breast Cancer, Stage II Breast Cancer
Interventions: Indocyanine Green Solution, Technetium Tc-99m Sulfur Colloid, Lymphoscintigraphy, Axillary Lymph Node Biopsy; Drug · Radiation · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: Lymphoseek; Drug
Lead sponsor: Navidea Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 13
States / cities: Birminham, Alabama • La Jolla, California • San Diego, California + 10 more

Conditions: Cancer
Interventions: EC0489, Injection, EC20; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: Lafayette, Indiana • Baltimore, Maryland • Bethesda, Maryland + 3 more

Conditions: Ovarian Cancer, Healthy Volunteers
Interventions: Tc 99m EC20; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging

A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects

A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)

Absorptive Clearance in the Cystic Fibrosis Airway

Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma

4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy

Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy

SentiMag® Intraoperative Comparison in Breast Cancer

Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid

An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer

Renal Uptake of Fatty Acids (FFA) in Patients With Idiopathic Uric Acid Nephrolithiasis (IUAN)

Imaging Airway Liquid Absorption in Cystic Fibrosis

Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition Approaches

99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404

Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial

Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH

Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism

Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Study of EC0489 for the Treatment of Refractory or Metastatic Tumors

Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients